Rupal Bhatt
Rupal Bhatt
Associate Professor
Verified email at
Cited by
Cited by
Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma
M Callea, L Albiges, M Gupta, SC Cheng, EM Genega, AP Fay, J Song, ...
Cancer immunology research 3 (10), 1158-1164, 2015
The high-dose aldesleukin “select” trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma
DF McDermott, SC Cheng, S Signoretti, KA Margolin, JI Clark, JA Sosman, ...
Clinical Cancer Research 21 (3), 561-568, 2015
A Drosophila CREB/ATF transcriptional activator binds to both fat body-and liver-specific regulatory elements.
T Abel, R Bhatt, T Maniatis
Genes & development 6 (3), 466-480, 1992
A mouse serine/threonine kinase homologous to C. elegans UNC51 functions in parallel fiber formation of cerebellar granule neurons
T Tomoda, RS Bhatt, H Kuroyanagi, T Shirasawa, ME Hatten
Neuron 24 (4), 833-846, 1999
Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma
RR McKay, GE Rodriguez, X Lin, MD Kaymakcalan, OPR Hamnvik, ...
Clinical Cancer Research 21 (11), 2471-2479, 2015
Discoidin domain receptor 1 functions in axon extension of cerebellar granule neurons
RS Bhatt, T Tomoda, Y Fang, ME Hatten
Genes & Development 14 (17), 2216-2228, 2000
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
L Zhang, M Bhasin, R Schor-Bardach, X Wang, MP Collins, D Panka, ...
PLoS One 6 (4), e19144, 2011
A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma
RS Bhatt, J Merchan, R Parker, HK Wu, L Zhang, V Seery, JV Heymach, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2010
Anti-S1P antibody as a novel therapeutic strategy for VEGFR TKI-resistant renal cancer
L Zhang, X Wang, AJ Bullock, M Callea, H Shah, J Song, K Moreno, ...
Clinical cancer research 21 (8), 1925-1934, 2015
KIR3DL3 is an inhibitory receptor for HHLA2 that mediates an alternative immunoinhibitory pathway to PD1
RS Bhatt, A Berjis, JC Konge, KM Mahoney, AN Klee, SS Freeman, ...
Cancer immunology research 9 (2), 156-169, 2021
Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
RS Bhatt, X Wang, L Zhang, MP Collins, S Signoretti, DC Alsop, ...
Molecular cancer therapeutics 9 (10), 2793-2802, 2010
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high‐risk localized prostate cancer: A Prostate Cancer Clinical Trials Consortium trial
RW Ross, MD Galsky, P Febbo, M Barry, JP Richie, W Xie, FM Fennessy, ...
Cancer 118 (19), 4777-4784, 2012
Angiopoietin 2 is a potential mediator of high-dose interleukin 2–induced vascular leak
DC Gallagher, RS Bhatt, SM Parikh, P Patel, V Seery, DF McDermott, ...
Clinical cancer research 13 (7), 2115-2120, 2007
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma
DC Cho, I Puzanov, MM Regan, T Schwarzberg, V Seery, MY Lee, V Liu, ...
Journal of immunotherapy 32 (2), 181-185, 2009
KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case–control study
G Scelo, DC Muller, E Riboli, M Johansson, AJ Cross, P Vineis, ...
Clinical Cancer Research 24 (22), 5594-5601, 2018
Statins and survival outcomes in patients with metastatic renal cell carcinoma
RR McKay, X Lin, L Albiges, AP Fay, MD Kaymakcalan, SS Mickey, ...
European Journal of Cancer 52, 155-162, 2016
Plasma cell-free DNA variant analysis compared with methylated DNA analysis in renal cell carcinoma
K Lasseter, AH Nassar, L Hamieh, JE Berchuck, PV Nuzzo, K Korthauer, ...
Genetics in Medicine 22 (8), 1366-1373, 2020
A phase 2 study of the sphingosine‐1‐phosphate antibody sonepcizumab in patients with metastatic renal cell carcinoma
SK Pal, HA Drabkin, JA Reeves, JD Hainsworth, SE Hazel, DA Paggiarino, ...
Cancer 123 (4), 576-582, 2017
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts
X Wang, L Zhang, A O'neill, B Bahamon, DC Alsop, JW Mier, SN Goldberg, ...
British journal of cancer 108 (2), 319-326, 2013
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement
A Gjyrezi, F Xie, O Voznesensky, P Khanna, C Calagua, Y Bai, J Kung, ...
The Journal of clinical investigation 130 (6), 3287-3298, 2020
The system can't perform the operation now. Try again later.
Articles 1–20